Guerreiro, Joao Paulo Fernandes [UNESP]Balbino, Jose Rodolfo MartinesRodrigues, Bruno PossaniDanieli, Marcus Vinicius [UNESP]Queiroz, Alexandre OliveiraCataneo, Daniele Cristina [UNESP]2022-04-282022-04-282021-01-01Acta Ortopedica Brasileira, v. 29, n. 6, p. 312-315, 2021.1413-7852http://hdl.handle.net/11449/223032Objective: To examine and compare the clinical efficacy of intraarticular epsilon aminocaproic acid (EACA) and tranexamic acid (TXA) in total knee arthroplasty (TKA). Methods: This study was a prospective, single-center, double-blinded randomized controlled trial, including sixty patients with osteoarthritis of the knee divided into two groups of 30 patients. In the TXA group, 1 g of TXA (0.05 g/ ml) was applied intraarticularly, and in the EACA group, 4 g of EACA (0.2 g/ml) was applied intraarticularly. Serum hemoglobin (Hgb) and hematocrit (Htb) were measured during the preoperatively and 24 and 48 hours postoperatively. The range of motion and pain were evaluated by clinical examination. To evaluate knee function before and 2 months after surgery, the Western Ontario and McMaster Universities Index (WOMAC) questionnaire was used. Results: In total, 56 (93.3%) patients were evaluated up to the second postoperative month. No significant difference between the groups (p > 0.05) was found in the decrease in Hgb or Htb at 24 or 48 hours. Regarding assessment of the pain, WOMAC score and gain in knee flexion, no significant advantages up to 60 days after surgery (p > 0.05) were found. Conclusions: The decrease risk of transfusion were similar with the intraarticular use of 1 g of TXA and 4 g of EACA in TKA. The possible benefits regarding knee pain, gain in flexion and function were also similar for the drugs. Level of Evidence II, Randomized, Double-Blinded, Clinical Trial.312-315engBleedingEpsilon Aminocaproic AcidPainTotal Knee ArthroplastyTranexamic AcidArtigo10.1590/1413-7852202129062420082-s2.0-85121011374